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To the Editor: This report aims to document possibly the first
isolation of Candida famata as a cause of human central nervous
system infection.
Yeasts and other medically important fungi cause various
clinical conditions ranging from trivial infestations to serious
life-threatening conditions. Candida species were demonstrated
as being the causative agents of oral thrush from as early as
18391 and thereafter recognised as causing a multitude of
infective disorders. With the advent of widespread oncological
treatment in the early 1960s1 and controlled iatrogenic immune
suppression for various other reasons, Candida spp. once again
arose as a formidable opportunistic human pathogen.
Emerging yeast infections have been described with increasing
frequency, with at least 17 species of the genus Candida now
being recognised as potential human pathogens. 1 With further
developments in medical intervention and the increasing
population of patients with immune deficiencies, whether
iatrogenic or acquired, such as HIV infection, the list of yeasts
that can cause disease will continue to grow. The flagship of
the genus Candida, namely C. albicans, is the most common
species isolated from blood cultures and blood-associated
infections1 especially in the nosocomial setting. For new
emerging yeast pathogens blood and catheter-associated
infections are common,1 although some species may cause
infection at other sites. Yeast infections of the central nervous
system caused by organisms other than Cryptococcus spp. are
uncommon, with Candida and Aspergillus species being the only
other noteworthy pathogens.2 The emerging yeast C. famata has
previously been described as a human pathogen, associated
with eye1 and intravenous catheter infections, 1 fungaemia3,4 and
peritonitis5 respectively.
Case report
A 29-year-old man presented to a community hospital with a 3-
week collateral history of feeling generally unwell. His main
complaint was a severe relentless headache with occasional
vomiting. At the time of admission he appeared neurologically
suppressed, not responding well to vocal commands, but still
responded briskly to painful stimuli. No further relevant
history could be elicited bar that he had not travelled recently.
Clinical examination revealed neck stiffness with both positive
Kernig’s and Brudzinski’s signs but no other signs of
pathology.A clinical diagnosis of bacterial meningitis was
made and treatment was commenced with cefotaxime,
administered intravenously.
Special investigations
A lumbar puncture performed shortly after admission revealed
slightly turbid, xanthochromic cerebrospinal fluid (CSF).
Biochemical investigation revealed CSF protein 28 580 mg/l
(normal range 150 - 450 mg/l), CSF chloride 106 mmol/l
(normal range 118 - 132 mmol/l) and CSF glucose 6.1 mmol/l
(normal range 2.2 - 3.9 mmol/l). Microscopic analysis of the
CSF sample revealed polymorphonuclear leucocytes (PMN)
5/µl (normal range 0 - 5/µl), lymphocytes 22/µl (normal range
0 - 10/µl),6 with no overt micro-organisms observed.
Cryptococcal and bacterial capsular antigen tests could not be
performed due to clotting of the CSF sample. Syphilis serology
was negative in the rapid plasma reagin (RPR), Treponema
pallidum haemagglutination (TPHA) and fluorescent
treponemal antibody absorption (FTA-abs) tests. HIV serology
was positive with the standard battery of one screening
enzyme-linked immunosorbent assay ELISA) and two
confirmatory ELISAtests.
Case-isolate identification
The CSF sample was plated onto appropriate semisolid agar
media according to standard microbiological operational
procedures.6 Within 72 hours positive growth was observed on
both chocolate and blood agar plates. Subsequent Gram
staining of the isolate revealed yeast cells, which were kept for
further mycological analysis and identification. This isolate was
inoculated onto the ID32C (Biomerieux SA, Marcy-l’Etoile,
France) yeast identification system according to the
manufacturer’s instructions. Two separate identifications
revealed C. famata with degrees of identification (specificity) as
stated by the manufacturer, of 99.9% and 99.8% respectively.
The use of the ID32C system has been proved previously to be
the most accurate for the identification of infrequently isolated
Candida species.7 No other microorganisms including
mycobacteria were isolated from this specimen.
Susceptibility testing
The case isolate was subjected to antifungal susceptibility
testing employing the Fungitest micro-broth dilution kit
(Biorad, Marnes la Coquette, France) according to the
manufacturer’s instructions. The C. famata strain was found to
be sensitive to all antifungal agents tested including: 5-
fluorocytosine, amphotericin B, miconazole, ketoconazole,
itraconazole and fluconazole, which is similar to the findings of
susceptibility studies published previously.8
Treatment
The patient’s clinical condition improved slightly during
hospitalisation to the extent that oral therapy with fluconazole
could commence 8 days after admission with a stat oral dose of
400 mg fluconazole, followed by 200 mg administered twice
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daily. Despite his initial recovery the patient’s condition
worsened and he died 12 days after admission.
Discussion
This case demonstrates that C. famata may act as a central
nervous system pathogen in immune-compromised
individuals.
A study conducted on mice previously treated with
cortisone9 demonstrated the organism’s potential to invade the
central nervous system under immune-compromising
conditions. Of these infected animals, 50% were killed while
this species proved non-pathogenic to normal mice with no
gross pathology, microscopic lesions or positive tissue cultures
at the end of the experiment.9
Our patient demonstrated a chronic clinical picture, with
CSF special investigations supporting the diagnosis of
meningitis caused by a fungal pathogen, with increased CSF
lymphocytes, elevated CSF-protein and positive fungal culture
being most suggestive. Fluconazole treatment for C. famata
infections has reported mixed success, 4,5 with one case of
successful treatment of catheter-associated fungaemia after
administration of amphotericin B.1 Successful therapy with
fluconazole for yeast infections usually requires intravenous
dosing, early commencement of therapy and an adequate
dosage, this patient being a case in point, with delayed
treatment and ineffective oral dosing probably leading to his
death. The role of HIV as an immunosuppressive condition
and possible co-factor for C. famata infection of the central
nervous system could not be further investigated due to the
death of the patient. C. famata is an uncommon human
pathogen with few documented infectious conditions. The case
presented shows the organism to be a possible novel pathogen
in the human central nervous system. Failure to identify and
recognise C. famata as a pathogen, combined with delayed
therapy, especially when occurring in immune-compromised
patients, may lead to unnecessary fatalities.
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To the Editor: In South Africa there is scepticism about the
feasibility of exclusive breast-feeding (EBF) — despite success
stories from Mexico, Bangladesh and Belarus. 1-3 We report on
the steps taken to develop a breast-feeding counselling and
support strategy, which supports EBF, in a rural subdistrict in
KwaZulu-Natal, where mixed feeding was the norm. Prior
research showed that traditional beliefs and concerns about
milk sufficiency or infant satiety/health were the main reasons
for mixed feeding.4
Between May and September 2000 we recruited matriculated
women, living in the subdistrict, as breast-feeding counsellors
(BCs). They were trained using the WHO/UNICEF breast-
feeding counselling training course, 5 a 40-hour course with a
strong counselling component. Knowledge before and after
training was assessed using a tool developed by the study
team. A field guide, containing information from the course
and appropriate suggestions addressing traditional beliefs that
hinder EBF, was developed as an aide-mémoire to facilitate
quality, consistent breast-feeding counselling. All BCs were
trained to use the field guide. BCs recruited pregnant or 
breast-feeding women at clinics, and visited them at home at
least once a week. The involvement of influential family
members during home visits was encouraged. During each
home visit, using the listening and learning skills from the
course,5 BCs asked how feeding was going, whether additional
feeds or fluids were given to the infant and reasons for these,
and about breast health. They observed a breast feed, and then
counselled the mother (and often the family) using ‘building
Exclusive breast-feeding — a pipe dream?
